Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A survey on clinical natural language processing in the United Kingdom from 2007 to 2022.
Wu H, Wang M, Wu J, Francis F, Chang YH, Shavick A, Dong H, Poon MTC, Fitzpatrick N, Levine AP, Slater LT, Handy A, Karwath A, Gkoutos GV, Chelala C, Shah AD, Stewart R, Collier N, Alex B, Whiteley W, Sudlow C, Roberts A, Dobson RJB. Wu H, et al. Among authors: chelala c. NPJ Digit Med. 2022 Dec 21;5(1):186. doi: 10.1038/s41746-022-00730-6. NPJ Digit Med. 2022. PMID: 36544046 Free PMC article. Review.
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Among authors: chelala c. Pharmacol Rep. 2023 Jun;75(3):753. doi: 10.1007/s43440-023-00487-z. Pharmacol Rep. 2023. PMID: 37195562 Free PMC article. No abstract available.
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Among authors: chelala c. Pharmacol Rep. 2023 Jun;75(3):570-584. doi: 10.1007/s43440-023-00480-6. Epub 2023 Apr 3. Pharmacol Rep. 2023. PMID: 37010783 Free PMC article.
Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R, Liu P, Chard Dunmall LS, Di Gioia C, Nagano A, Cutmore L, Wang J, Chelala C, Nyambura LW, Walden P, Lemoine N, Wang Y. Brito Baleeiro R, et al. Among authors: chelala c. J Immunother Cancer. 2023 Aug;11(8):e007336. doi: 10.1136/jitc-2023-007336. J Immunother Cancer. 2023. PMID: 37586771 Free PMC article.
Dynamic Biobanking for Advancing Breast Cancer Research.
Abdollahyan M, Gadaleta E, Asif M, Oscanoa J, Barrow-McGee R, Jones S, Jones LJ, Chelala C. Abdollahyan M, et al. Among authors: chelala c. J Pers Med. 2023 Feb 18;13(2):360. doi: 10.3390/jpm13020360. J Pers Med. 2023. PMID: 36836597 Free PMC article.
The molecular landscape of pancreatic ductal adenocarcinoma.
Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Sivapalan L, et al. Among authors: chelala c. Pancreatology. 2022 Nov;22(7):925-936. doi: 10.1016/j.pan.2022.07.010. Epub 2022 Jul 21. Pancreatology. 2022. PMID: 35927150 Free article. Review.
157 results